[HTML][HTML] Duration of viable virus shedding and polymerase chain reaction positivity of the SARS-CoV-2 Omicron variant in the upper respiratory tract: a systematic …

Y Wu, Z Guo, J Yuan, G Cao, Y Wang, P Gao… - International Journal of …, 2023 - Elsevier
Objectives To assess the duration of viable virus shedding and polymerase chain reaction
(PCR) positivity of the SARS-CoV-2 Omicron variant in the upper respiratory tract. Methods …

[HTML][HTML] Safety and efficacy of Paxlovid against Omicron variants of coronavirus disease 2019 in elderly patients

C Weng, R Xie, G Han, Y Yuan, S Li, C Wang… - Infectious Diseases and …, 2023 - Springer
Introduction Elderly patients are the most affected and vulnerable to COVID-19 and effective
therapeutic interventions are urgently required. We clarified the safety and efficacy of …

[HTML][HTML] A review on the impact of the SARS-CoV-2 Omicron subvariant on elderly patients with diverse co-morbidities

A Khadela, S Soni, K Megha, S Bhagat, VP Chavda - Biologics, 2023 - mdpi.com
The SARS-CoV-2 virus has caused a catastrophic impact on the world for the past 3 years.
The virus has now returned with the emergence of the Omicron (B. 1.1. 529) variant. Within …

The unreversible reduced but persistent activated NK and CD8+ T cells in severe/critical COVID-19 during omicron pandemic in China

L Qin, X Duan, JZ Dong, Y Chang, Y Han… - Emerging microbes & …, 2023 - Taylor & Francis
As a hallmark of COVID-19 progression, lymphopenia alongside its subtle immune
disturbance has been widely reported, but yet to be thoroughly elucidated. Aiming at …

[HTML][HTML] Effectiveness of paxlovid, an oral antiviral drug, against the Omicron BA. 5 variant in Korea: severe progression and death between July and November 2022

JM Kim, MG Yoo, SJ Bae, J Kim… - Journal of Korean Medical …, 2023 - ncbi.nlm.nih.gov
Background Paxlovid is an oral antiviral drug that received emergency use authorization in
South Korea for the treatment of patients with mild-to-moderate coronavirus disease 2019 …

Oral azvudine (FNC) tablets in patients infected with SARS-CoV-2 omicron variant: a retrospective cohort study

W Chen, H Xu, L Hong, R Yang, C Peng, G Wang, W Li - MedRxiv, 2023 - medrxiv.org
Background There is a lack of data on the efficacy of oral Azvudine in Coronavirus Disease
treatment. This study aimed to assess the association between Azvudine treatment and …

[HTML][HTML] Update on Omicron variant and its threat to vulnerable populations

B Dai, W Ji, P Zhu, S Han, Y Chen, Y Jin - Public Health in Practice, 2024 - Elsevier
Objective To reduce the incidence of severe illness and fatalities, and promote the
awareness of protection and precaution, increased vaccination, strengthen the physical …

Antibody response to inactivated COVID‐19 vaccine in patients with type 2 diabetes mellitus after the booster immunization

H Li, Y Wang, X Li, S Wang, X Feng, X Xiao… - Journal of …, 2023 - Wiley Online Library
Background The immunogenicity of booster inactivated COVID‐19 vaccines in patients with
type 2 diabetes mellitus (T2DM) has remained unclear. Our study aims to investigate the …

[HTML][HTML] Understanding clinical characteristics influencing adverse outcomes of Omicron infection: a retrospective study with propensity score matching from a …

Y Geng, Q Nie, F Liu, Y Pei, Q Chen… - Frontiers in Cellular …, 2023 - frontiersin.org
Objectives. The epidemic of coronavirus disease 2019 (COVID-19) is causing global health
concerns. The aim of this study was to evaluate influence of clinical characteristics on …

The Efficacy and Safety of Shashen-Maidong Decoction Combined with Western Medicine in the Treatment of Omicron Infected Individuals Over 85 Years Old: A …

XX Lin, YQ Yin, WZ Zhang, JH Huang… - Infection and Drug …, 2023 - Taylor & Francis
Background During the Omicron variant outbreak of COVID-19 (2022–2023), Chinese
healthcare institutions combined traditional Chinese medicine (TCM) with Western medical …